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ABSTRACT 
 
Ribonucleotide reductase (RR) has an essential role in DNA synthesis and repair and is a therapeutic target in a 
number of different cancers.  Previous studies have shown that RNAi-mediated knockdown of either the RRM1 
or RRM2 subunit sensitizes cells to the cytotoxic effects of the nucleoside analogs and more recently it has 
been shown that RRM2 knockdown itself has a growth inhibitory effect. Here we compare the effects of 
siRNA-mediated knockdown of both RRM1 and RRM2 subunits of RR in A549 and HCT-116 cells using an 
optimized transfection protocol. Growth of A549 cells was strongly inhibited by efficient siRNA-mediated 
silencing of either RRM1 or RRM2, and knockdown of each subunit led to long-term growth inhibition and 
cell-cycle arrest. Knockdown with sub growth inhibitory siRNA concentrations sensitized A549 and HCT-116 
cells to gemcitabine when RRM1 was targeted, whereas RRM2 knockdown led to hydroxyurea sensitization. 
These results suggest that the inhibition of cell growth, rather than drug sensitization, is the major effect of 
RRM1 and RRM2 knockdown. In an A549 xenograft model, cells transfected with RRM1-specific siRNA 
failed to form tumors in 6 out of 8 CD1 nude mice, whereas those transfected with RRM2-specific siRNA grew 
but at a reduced rate. Taken together, these data demonstrate that siRNA-mediated knockdown of the RRM1 
subunit is more effective than knockdown of RRM2 in inhibiting the growth of cancer cell lines and suggest 
that RRM1 is a potential target for nucleic acid-based cancer therapies, either alone or in combination with 
gemcitabine. 
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INTRODUCTION 
 
In order for DNA replication and repair to proceed, cells 
must  synthesize  sufficient  quantities  of  2’-deoxyribo-
nucleotide precursors. Their generation by reduction of the 
corresponding  ribonucleotides,  the  rate-limiting  step  in 
DNA synthesis, is the preserve of ribonucleotide reductase 
(RR). RR is a tightly regulated tetrameric enzyme consisting 
of homodimers of the RRM1 and RRM2 subunits, both of 
which  are  required  for  the  formation  of  the  active  site 
(Nordlund  and  Reichard,  2006).  RRM1  is  constitutively 
expressed,  whereas  RRM2  is  expressed  in  a  cell  cycle-
dependent  manner,  with  expression  beginning  in  S-phase 
and peaking in mitosis, after which it is rapidly degraded.  
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An RRM2 paralog, p53R2 (or RRM2B), is activated by p53 
following genotoxic stress and is involved in DNA repair 
(Xue et al, 2003).  
 
RR  has  long  been  targeted  with  anti-cancer  therapies, 
including  hydroxyurea  and  the  nucleoside  analog 
gemcitabine.    These  drugs  have  distinct  mechanisms  of 
action on RR. Hydroxyurea is a specific reversible inhibitor 
that  interferes  with  radical  formation  essential  to  the 
catalytic activity of the enzyme. In contrast, gemcitabine is a 
substrate analog which competitively inhibits de novo DNA 
synthesis.  RRM1  (Davidson  et  al,  2004;  Jordheim  et  al, 
2005) and RRM2 ( Zhou et al, 1995; Goan et al, 1999) were 
found to be upregulated in cell lines resistant to gemcitabine 
and  hydroxyurea,  respectively.  In  addition,  RRM1  was 
found  upregulated  following  in  vivo  selection  with 
gemcitabine (Bergman et al, 2005).  
 
Despite the central role of RR in cancer cell growth, there 
are  conflicting  reports  as  to  its  contribution  to 
tumorigenesis.  Expression  of  RRM1  and  RRM2  is 
suppressed by the retinoblastoma tumor suppressor (pRB) 
and loss of pRB in tumor cells is associated with increased 
dNTP  levels  and  resistance  to  5-fluorouracil  (5-FU)  and 
hydroxyurea (Angus et al, 2002). Other reports suggest that 
RRM1  has  a  tumor  suppressor  role  and  inhibits  growth 
when expressed at high levels (Cao et al, 2003).  
 
Previous studies in which RRM1 or RRM2 expression was 
inhibited using antisense oligodeoxynucleotides (AS-ODN) 
(Chen et al, 2000; Lee et al, 2003; Lee et al, 2006) or RNAi 
(Duxbury  et  al,  2004a;  Duxbury  et  al,  2004b;  Lin  et  al, 
2004; Bepler et al, 2006; Oguri et al, 2006) showed varying 
levels of growth inhibition, and RNAi-mediated knockdown 
of RRM1 or RRM2 also sensitized cells to gemcitabine or 
hydroxyurea,  respectively  (Bepler  et  al,  2006;  Lin  et  al, 
2007).  Similarly,  inhibiting  the  expression  of  the  p53R2 
subunit was shown to enhance 5-FU toxicity in oral cancer 
cell lines (Yanamoto et al, 2005). The promise of molecular 
inhibition of RR has led to AS-ODN against each subunit 
reaching clinical trial for non-small cell lung cancer (Desai 
et al, 2005; Juhasz et al, 2006).  
 
Considering  the  apparent  non-redundant  central  role  of 
RRM1  in  DNA  synthesis,  it  is  surprising  that  previous 
reports of siRNA-mediated reduction in RRM1 expression 
showed only a  modest  growth inhibitory effect on tumor 
cells (Nakahira et al, 2007). Initial studies on the silencing 
of RRM2 reported similar effects; more recently, however, 
RRM2  silencing  has  been  shown  to  inhibit  tumor  cell 
growth both in vitro and in vivo (Avolio et al, 2007; Heidel 
et  al,  2007).  We  have  used  synthetic  siRNAs  to  further 
investigate  the  role  of  RRM1  on  the  growth  and 
chemoresistance  of  cancer  cell  lines,  compared  with 
knockdown  of  RRM2.  By  using  optimized  transfection 
conditions, we found that inhibiting the expression of either 
RRM1 or RRM2 with nanomolar concentrations of siRNA 
had a strong inhibitory effect on the growth of cancer cell 
lines  derived  from  a  range  of  tumors;  at  low  picomolar 
concentrations the siRNAs no longer inhibited growth but 
caused  subunit-specific  effects  on  sensitization  to 
hydroxyurea and gemcitabine. These observations suggest 
that,  with  appropriate  tumor-selective  delivery,  a  nucleic 
acid-based  strategy  targeting  RRM1  could  form  a  viable 
therapeutic strategy against a variety of tumor types. 
 
MATERIALS AND METHODS 
 
Cell lines and chemicals 
The A549 and HCT-116 cell lines used in this study were 
obtained  from  ATCC.  Cells  were  grown  in  RPMI-1640 
medium supplemented with 10% (v/v) heat-inactivated fetal 
bovine  serum  (FBS)  (both  from  Invitrogen  Corporation, 
Carlsbad, CA), at 37ºC in humidified air with 5% (v/v) CO
2. 
Hydroxyurea  was purchased from  Sigma (St  Louis, MO) 
and gemcitabine was obtained from Eli Lilly (Indianapolis, 
IN).  SYBR®  Green I  and  Hoechst  33342  were  from 
Invitrogen Corporation. All other chemicals were purchased 
from Sigma.  
 
siRNAs and transfection 
All siRNAs and transfection reagents were purchased from 
Invitrogen.  The  siRNAs  used  were  blunt-ended  25 
nucleotide  duplexes  with  sense  strands  modified  by 
Invitrogen’s  proprietary  Stealth
TM  technology.  Three 
independent  siRNAs  targeting  RRM1  and  RRM2  were 
used. See below for guide strand sequences (5’ ￿ 3’). 
 
siRNAs targeting RRM1: 
RRM1-1: AUUCAAAGAUGUCUAAAUGCCAAGG 
RRM1-2: AAGAUCUGCUUAUUCAGUAACUGGG 
RRM1-3: UAGAAGUGCAUACUAGUGAGUUUGC 
 
siRNAs targeting RRM2: 
RRM2-1: UGUACCAGGUGUUUGAACAUCAGGC 
RRM2-2: AAUUCAUCCCAAUGAGCUUCACAGG 
RRM2-3: UUAUACAUCUGCCAGAUAUCAUGGU 
 
Non-targeting controls: 
81-ctrl: CCACACGAGUCUUACCAAGUUGCUU 
809-ctrl: AAAUCAAUGGGAGGAGACAUUUCCC 
RRM1-REV: CCCAGUUACUGAAUAAGCAGAUCUU 
 
Transfection  of  each  cell  line  was  first  optimized  by 
measuring  the  level  of  FITC-labeled  Block-iT
TM  duplex 
introduced  with  the  transfection  reagent  Lipofectamine
TM 
2000  (L2K),  using  flow  cytometry  (see  below).  Once 
optimal  conditions  were  determined,  Lipofectamine
TM 
RNAiMax, a reagent optimized for siRNA transfection but 
incompatible  with  FITC  fluorescence  measurements,  was 
used in all subsequent experiments to introduce Stealth
TM 
siRNAs into cells via reverse transfection. Briefly, siRNAs 
and  Lipofectamine  were  diluted  in  RPMI  without  serum, 
and  incubated  for  5-10  min  at  room  temperature.  After 
optimization,  a  Lipofectamine  concentration  of  0.8  µl/ml 
was  used  for  transfections  with  all  cell  lines.  The 
Lipofectamine mix was added drop-wise to the siRNA, and 
lipoplex formation was allowed to proceed for 20-30 min at 
room  temperature.  Lipoplexes  were  then  transferred  to 
multi-well tissue culture plates and, unless otherwise noted, 
overlaid  with  5x10
3  cells/cm
2.  Following  overnight 
incubation,  the  transfection  medium  was  replaced  with 
RPMI containing 10% (v/v) FBS, and cells were analyzed at 
indicated  time  points.  Where  required,  cells  were  further 
treated  with  chemotherapeutic  drugs  as  described  in  the 
figure legends.  
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Real-time PCR  
RNA  was  purified  from  cells  using  PureLink  96  RNA 
Purification  kit  as  per  the  manufacturer’s  protocol 
(Invitrogen).  First-strand  cDNA  was  generated  using  the 
SuperScript®  VILO  cDNA  Synthesis  kit  (Invitrogen), 
from  approximately  140ng  purified  RNA.  For  semi-
quantitative  RT-PCR,  the  cDNA  was  diluted  1:4  in 
ultraPURE™ RNase-free water, and real-time PCR carried 
out on a LightCycler® 480 II (Roche) using LightCycler® 
480 SYBR Green I Master Mix (Roche) and gene- specific 
primers at 180 nM. Levels of RRM1 and RRM2 mRNA 
were  normalized  to  the  housekeeping  gene  LMNA,  and 
change  in  mRNA  following  transfection  with  specific 
siRNAs compared to control siRNAs was calculated. The 
following primers were used: 
 
RRM1 forward primer: 
5’ GGCAAACTCACTAGTATGCACTTC 
 
RRM1 reverse primer:  
5’ AAATAATACATCCCAGTCTTCAAACC 
 
RRM2 forward primer: 
5’ CAGCAAGCGATGGCATAGT 
 
RRM2 reverse primer: 
5’ AGCGGGCTTCTGTAATCTGA 
 
LMNA forward primer: 
5’ TGAGGCCAAGAAGCAACTTCA 
 
LMNA reverse primer: 
5’ CTCATGACGGCGCTTGGT.  
 
Western blotting 
Cells were  harvested 48  or  72  hr  post-transfection  with 
RRM1- or RRM2-specific or control siRNAs, and lysates 
were prepared in lysis buffer (150 mM NaCl, 50 mM Tris 
HCl pH 7.4, 1%, v/v NP40) supplemented with a protease 
inhibitor  cocktail  (Roche).  Following  quantification  using 
the BioRad’s  Protein  Assay kit  10  µg  of total protein/lane 
was  loaded  and  separated  by  electrophoresis  on  a  pre-
cast 10% polyacrylamide gel (Invitrogen) and blotted onto 
an Immobilon
TM-P  PVDF membrane  (Millipore).  After 
blocking  for  1  hr  with 5%  (w/v)  bovine  serum  albumin 
(BSA) in phosphate-buffered saline (PBS) containing 0.1% 
(v/v) Tween-20, membranes were probed with a goat anti-
human  polyclonal  antibodies  specific  for  RRM1  (T-16, 
Santa  Cruz),  RRM2  (N-18,  Santa  Cruz)  (both  used  at 
0.3 µg/ml) and GAPDH (V-18, Santa Cruz, 0.1 mg/ml) in 
PBS containing 2.5% (w/v) BSA and 0.1% (v/v) Tween-20. 
HRP-conjugated  donkey  anti-goat  IgG  (Santa  Cruz) was 
used as a secondary antibody at 80 ng/ml, and the signal 
was  detected  with ECL-Plus
TM  estern  Blotting  Detection 
System (GE Healthcare) on the ImageQuant scanner (GE 
Healthcare). 
 
Growth assays  
To  measure  the  effects  of  siRNA-mediated  RRM1  and 
RRM2 knockdown on cell growth, cellular DNA content 
was measured using a SYBR® Green I-based fluorometric 
assay.  At  the  indicated  time  points  following  reverse 
transfection,  replicate  plates  were  frozen  at  -80ºC  for 
subsequent analysis. For assays in which cells were treated 
with  a  combination  of  siRNA  and  gemcitabine  or 
hydroxyurea,  cells  24  hr  post-transfection  were  treated 
continuously  for  72  hr  with  the  indicated  concentrations, 
after which plates were frozen at -80ºC for later analysis. At 
the completion of the assay, frozen cells were thawed and 
cell lysis buffer (10 mM Tris HCl pH 8.0 containing 2.5 
mM EDTA, 1%, v/v, TritonTM X-100) and SYBR® Green 
I  (1:4000,  v/v)  were  added  to  the  wells  and  incubated 
overnight in the dark at 4ºC. The following day, cell lysates 
were  mixed  thoroughly,  and  DNA  fluorescence  was 
measured  with  a  Wallac  Victor
2  plate  reader  (Turku, 
Finland)  set  at  an  excitation  frequency  of  485  nm  and 
measuring emission at 535 nm. 
 
Flow cytometry 
To  determine  the  efficiency  with  which  siRNAs  were 
introduced following transfection, cells were analyzed for 
uptake  of  the  fluorescent  FITC-labeled  Block-iT
TM 
oligonucleotides  by  flow  cytometry.  The  day  following 
transfection, cells were resuspended in FACS buffer (PBS 
containing 1%, w/v, BSA and 0.1%, w/v, sodium azide) and 
cell-associated fluorescence was measured using a Becton 
Dickinson LSR II. For cell cycle analysis post transfection, 
cells were washed with FACS buffer and fixed on ice with 
4%  (v/v)  methanol  solution  in  PBS,  after  which  samples 
were stored at -20°C for at least 24 hr prior to staining with 
propidium  iodide  (5  µg/ml)  for  DNA  content  analysis.  
Cells were stained for 2 hr at 37ºC prior to flow cytometric 
analysis using a Becton Dickinson LSR II with a 96-well 
autosampler attached. Using pulse width/area analysis of the 
Hoechst  fluorescent  signal,  cycling  and  apoptotic  single 
cells were identified. 
 
A549 xenograft model  
A549  cells  in  vitro  were  reverse-transfected  with 
Lipofectamine
TM  RNAiMAX  and  an  RRM1-  or  RRM2-
specific siRNA or a non-targeting control siRNA, at a final 
siRNA concentration of 10 nM. Untreated cells served as an 
additional control. The following day, cells were detached 
from flasks with trypsin-EDTA, and the enzymatic reaction 
was stopped by the addition of FBS. After two washes with 
PBS, the cells were resuspended in PBS at a final density of 
8x10
7 cells/ml. Using a 26-gauge needle, groups of CD-1 
nude mice were injected subcutaneously on the flank with 
100  µl  of  the  cell  suspension  (equivalent  to  8x10
6  A549 
cells). The effect of RRM1 or RRM2 knockdown on tumor 
growth was assessed at the indicated intervals by measuring 
tumor size with digital calipers. Measurements were used to 
calculate the tumor volume using the formula: 0.52 x a
2b, 
where a = minor diameter and b = major diameter. 
 
RESULTS 
 
Effective  siRNA  delivery  into  cells  by  reverse 
transfection 
In many transfection protocols, a substantial number of cells 
do  not  receive  nucleic  acid,  and  this  untransfected  sub-
population  can  mask  the  effects  of  target  knockdown.  In 
order to better measure the effects on cell growth of RRM1 
and RRM2 knockdown, we first optimized our transfection 
conditions  to  maximize  the  number  of  cells  receiving 
siRNA by tracking the uptake of the FITC-labeled Block- 
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iT
TM  siRNA  by  flow  cytometry  following  reverse 
transfection  (cells  added  to  siRNA/L2K  mix)  or  forward 
transfection  (cells  plated  the  day  before  addition  of 
siRNA/L2K). As seen in Figure 1A, compared with control 
untransfected  cells  (top  panel)  the  reverse  transfection 
approach used here achieved close to 100% transfection in 
A549 cells (bottom panel), whereas with standard forward 
transfection,  a  substantial  untransfected  population 
remained  (middle  panel).  Transfection  rate  was  also 
dependent on cell density, as the proportion of transfected 
cells in the population clearly increased as the number of 
cells  in  the  transfection  reaction  decreased  (Figure  1B). 
Compared with untransfected cells (top panel), transfecting 
cells at a cell density of 20x10
3 cells per cm
2 yielded 72% 
transfected  cells  (second  panel),  increasing  to  93%  when 
10
4  cells  were  transfected  (third  panel),  and  greater  than 
99%  when  a  cell  density  of  5x10
3  cells/cm
2  was  used 
(bottom panel). Similar results were obtained with HCT-116 
cells (data not shown). These data directed the subsequent 
transfection  experiments,  in  which  cells  were  reverse-
transfected at a density of 5x10
3 cells/cm
2. 
 
Effective  knockdown  of  RRM1  and  RRM2  by  three 
independent siRNAs 
Using  the  optimized  transfection  conditions  described 
above,  cells  were  transfected  with  three  independent 
siRNAs specific for RRM1 or RRM2 and the reduction in 
mRNA and protein levels of these genes was analyzed.  As 
seen by real-time PCR in Figure 1C, expression of RRM1 
mRNA was reduced by greater than 90% 24 hr following 
transfection with three independent siRNAs (RRM1-1, -2 
and -3). RRM2-targeting siRNAs (RRM2-1, -2 and -3) were 
also  potent  inhibitors  of  mRNA  expression,  with  greater 
than  85%  reduction  in  RRM2  levels  with  5  nM  siRNA 
(Figure 1C). Western blot analysis showed that RRM1 and 
RRM2  protein  levels  were  also  strongly  decreased  48  hr 
after  transfection  with  subunit-specific  siRNAs  at  a 
concentration  of  5 nM  (Figure  1D).  In  each  case, 
knockdown  mediated  by  the  RRM1-  or  RRM2-specific 
siRNAs was limited to the targeted subunit with no effect 
on the other subunit (Figure 1D).  
 
RR knockdown compromises cancer cell growth 
To investigate the effects of RR silencing on cell growth, 
A549  cells  were  transfected  with  RRM1-  or  RRM2-
targeting siRNAs and their proliferation was followed over 
time. A strong inhibitory effect on the growth of both cell 
lines  was  seen  when  compared  with  controls,  with  cell 
numbers static for at least 5 days after transfection with 1 
nM siRNA (Figure 2A). Growth inhibition was observed for 
at  least  8  days  when  cells  were  transfected  with  10  nM 
RRM2-specific  siRNAs  and  for  at  least  10  days  when 
RRM1 was silenced with siRNAs the same concentration 
(Figure 2B). The potency of growth inhibition caused by 
silencing RRM1 or RRM2 was tested by measuring growth 
of A549 cells after transfection with varying concentrations 
of  RRM1- or  RRM2-specific siRNAs. Effects on  growth 
were dose-dependent and silencing was potent. At 96 hR 
post transfection, 50% growth inhibition was achieved with 
as little as 25-30 pM RRM1-2 or RRM1-3 siRNA; the third 
siRNA  RRM1-1  required  150  pM  for  the  same  effect 
(Figure 2C). RRM2 silencing was moderately less potent, 
with transfection of 100 pM of either RRM2-1 or RRM2-3, 
or 300 pM of RRM2-2, necessary to inhibit growth by 50% 
(Figure 2D). 
 
As  the  inhibition  of  RRM1  or  RRM2  clearly  had  an 
inhibitory effect on cell growth, we further investigated the 
mechanism of action of RRM1 and RRM2 silencing using 
flow  cytometry-based  cell  cycle  analysis  of  A549  cells 
treated with RRM1 or RRM2-specific, or control siRNA. 
Arrest  of  the  cell  cycle  occurred  within  48  hr  in  cells 
transfected  with  1  nM  RRM1-2  siRNA,  and  persisted  in 
those surviving for 96 hr, whereas transfection with 1 nM 
control  siRNA  had  no  effect  on  cell  cycle  distribution 
(Figure  3).  When  RRM1-2  siRNA  was  used  at  a 
concentration of 0.1 nM,,the initial cell cycle arrest was less 
pronounced and by 96 hr the cell cycle had begun to return 
to a normal distribution. In comparison, treating cells with 1 
nM  RRM2-1  siRNA also led to arrest, but this began to 
reverse by 96 hr. At a concentration of 0.1 nM, RRM2-1 
siRNA did not induce an observable change in cell cycle. 
 
Sub-growth inhibitory knockdown of RRM1 and RRM2 
sensitizes cells to drugs 
In previous studies, knockdown of RRM1 or RRM2 was 
shown  to  reverse  the  resistance  of  gemcitabine-selected 
cells.  We  also  observed  a  substantial  sensitization  to 
gemcitabine  in  cells  transfected  with  RRM1-targeting 
siRNA, but only when the siRNA concentration was below 
that required for growth inhibition (Table 1, Figure 4). A549 
and  HCT-116  cells  were  sensitized  to  gemcitabine  in  a 
dose-dependent manner following RRM1 knockdown with 
a final concentration of 10, 20 or 30 pM RRM1-1 siRNA 
(Figure 4A).  RRM1  silencing increased the  sensitivity of 
A549 and HCT-116 cells 2 to 5-fold compared with control 
siRNA-transfected  cells  (Table  1),  whereas  RRM2 
knockdown using a final concentration of 20, 40 or 50 pM 
RRM2-1 siRNA  had no effect on gemcitabine sensitivity 
(Figure  4B).  In  both  cases,  the  three  different  picomolar 
concentrations of siRNA used were insufficient to inhibit 
growth,  as  seen  in  Figure  3.  In  contrast,  hydroxyurea 
sensitization  was  observed  after  partial  knockdown  of 
RRM2, but not RRM1 (Figure 4C and D). Again, the 2 to 6-
fold  sensitization  (Table  1)  varied  in  a  dose-dependent 
manner with the final concentration of siRNA used, with 
knockdown  of  either  RRM1  or  RRM2  at  these  siRNA 
concentrations insufficient to inhibit growth in the absence 
of drug.  
 
Effect of RR knockdown on xenograft tumor growth in 
nude mice 
To investigate the effects of RRM1 knockdown on tumor 
growth, A549 cells, either untransfected or transfected with 
10 nM RRM1-2, RRM2-1 or control siRNA were implanted 
in CD-1 mice 24 hr after transfection. In mice implanted 
with the untransfected and control siRNA-transfected cells, 
tumors  formed  in  8  of  8  mice  injected;  in  the  RRM1 
transfected group, tumors formed in only 2 of 8 mice. The 
two tumors that did form in the RRM1 group were very 
slow-growing with little increase in volume over the course 
of the experiment (see Figure 5A). In contrast, when cells 
transfected  with  10  nM  RRM2  siRNA  were  implanted, 
tumors formed in all 8 mice. These tumors grew, but at a 
reduced rate compared with the tumors derived from control 
siRNA-transfected and untransfected cells (Figure 5B).  
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Figure 1. Reverse transfection is highly efficient in delivering siRNAs and enables effective RR knockdown. (A) FITC-labeled Block-iT 
was introduced into cells by either forward (middle) or reverse transfection (bottom) and compared to mock transfection control (top) 
and cell-associated fluorescence was analyzed by flow cytometry 24 hr later. (B) Cells at different plating densities were reverse 
transfected with Block-iT and cell-associated fluorescence was analyzed by flow cytometry 24 hr later. Cell density was 5, 10 or 20 x 10
3 
cells per cm
2 (panels 2-4), with untransfected control in panel 1. M1 and M2 are gates corresponding to untransfected and transfected 
cells, respectively. (C) Cells were transfected with siRNAs (5 nM) targeting RRM1 (1-1, 1-2 and 1-3) or RRM2 (2-1, 2-2 and 2-3), or 
81-ctrl control siRNA (C), or were untransfected (N), and RRM1 and RRM2 mRNA levels were quantified 24 hr later by real-time PCR 
and normalized to the expression of LMNA. (D) Protein expression was measured by western blot at 48 hr post-transfection with RRM1- 
or RRM2-specific or 81-ctrl control siRNAs at a final concentration of 5 nM. Following detection of RRM1 or RRM2, membranes were 
stripped and probed with GAPDH antibodies. 
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Figure 3. RR knockdown induces cell-cycle arrest and apoptosis. The cell cycle distribution in A549 cells was analyzed over 96 hr 
following transfection with control siRNA, or siRNAs specific for RRM1 (1-2) or RRM2 (2-1) at a final concentration of 0.1 and 1 
nM. After harvesting every 24 hr, cells were fixed in methanol (70%, v/v) and then stained with propidium iodide and analyzed as 
described in Materials and Methods. The results from one experiment are shown; a second experiment generated similar results. 
Figure 2. RRM1 and RRM2 
siRNAs mediate long lasting and 
potent growth inhibition. 
To measure growth inhibition, 
A549 cells were transfected with 1 
nM (A) or 10 nM (B) of three 
different RRM1-specific siRNAs 
[1-1 (▲), 1-2 (■) 1-3 (♦)] or 
RRM2-specific siRNAs [2-1 (∆), 2-
2 (□), 2-3(◊)] or control siRNA (*) 
and growth over 10 days was 
determined by measuring total 
DNA per well at the indicated time 
points. To assess the potency of 
growth inhibition, cells were 
transfected with siRNA targeting 
RRM1 (C) or RRM2 (D) at a range 
of concentrations (starting at 5 nM 
with sequential 2-fold dilutions to 
19 pM) and growth at 96 hr post-
transfection was determined by 
quantifying total DNA per well and 
relating this to cells transfected 
with equivalent concentrations of 
control siRNA (A). Data are mean 
± SEM of values from three wells, 
and are representative of three 
independent experiments.  
©The Authors | Journal of RNAi and Gene Silencing | June 2009 | Vol 5, No 1 | 321-330 | OPEN ACCESS 
327 
Table 1. Drug toxicity following RRM1 and RRM2 knockdown  
 
 
# Values are nM for gemcitabine and mM for hydroxyurea. Data are the mean ±SEM from two independent experiments; 
+ The change 
in IC50 value in cells treated with RRM1 or RRM2-specific siRNA compared with those treated with control siRNA; * p < 0.05, 
Student’s t-test 
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Figure 4. Sensitization to drugs following RR knockdown.  A549 cells were transfected with: 10 (♦), 20 (▲) or 30 nM (■) RRM1-
specific siRNA (1-2) (A, C); 20 (♦), 40 (▲) or 50 nM RRM2-specific siRNA (2-1) (■) (B, D); or 1 nM 81-ctrl siRNA (○). Following 
transfection, cells were treated with 0.19-6 nM gemcitabine (A, B) or 0.18-1 mM hydroxyurea (C,D), and after 4 days, proliferation 
was measured by quantifying the DNA content in each well, and was the mean fluorescence ±SEM from three replicate wells. Data 
are represented as growth of transfected drug-treated cells as a percentage of transfected cells that were not exposed to drug, and are 
from one of three experiments giving similar results. 
    A549  HCT-116 
   siRNA (concentration)  IC50
#  fold 
change
+  IC50  fold 
change 
Gemcitabine  RRM1-2 (0.01 nM)  2.03 ± 0.20  2.2*  1.18 ± 0.53  1.8 
  RRM1-2 (0.02 nM)  1.13 ± 0.15  3.9*  0.69 ± 0.08  3.0* 
  RRM1-2 (0.03 nM)  0.80 ± 0.25  5.5*  0.46 ± 0.10  4.5* 
  809-ctrl (1 nM)  4.39 ± 1.08    2.08 ± 0.34   
  RRM2-1 (0.02 nM)  4.09 ± 0.91  1.1  2.26 ± 0.22  0.9 
  RRM2-1 (0.04 nM)  3.80 ± 1.99  1.2  2.40 ± 0.30  0.9 
  RRM2-1 (0.05 nM)  4.18 ± 1.60  1.1  2.48 ± 0.65  0.8 
  809-ctrl (1 nM)  4.39 ± 1.08    2.08 ± 0.34   
Hydroxyurea  RRM1-2 (0.01 nM)  0.22 ± 0.01  1.0  0.35 ± 0.18  1.1 
  RRM1-2 (0.02 nM)  0.25 ± 0.03  0.9  0.24 ± 0.14  1.6 
  RRM1-2 (0.03 nM)  0.18 ± 0.01  1.2  0.19 ± 0.09  2.1 
  809-ctrl (1 nM)  0.22 ± 0.01    0.39 ± 0.12   
  RRM2-1 (0.02 nM)  0.13 ± 0.01  1.7*  0.21 ± 0.04  1.9* 
  RRM2-1 (0.04 nM)  0.05 ± 0.02  4.8*  0.06 ± 0.01  6.5* 
  RRM2-1 (0.05 nM)  0.04 ± 0.02  6.1*  0.08 ± 0.03  4.8* 
  809-ctrl (1 nM)  0.22 ± 0.01    0.39 ± 0.12    
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Figure 5. Effect of RRM1 knockdown on xenograft tumor formation. A549 cells were transfected with 10 nM of control siRNA (○), 
RRM1- or RRM2-specific siRNA (●), or untransfected (□) 24 hr prior to injection into CD-1 nude mice. In (A), cells transfected with 
RRM1-2 or control siRNA, along with untransfected controls, were implanted into mice, and in (B) RRM2-1-transfected cells were used 
along with controls. Tumor volume was measured on the indicated days. Values represent mean ±SEM of 5 mice. * p < 0.01 and 
# p = 
0.05 compared with 81-control siRNA-transfected cells (Student’s t-test). 
 
 
 
DISCUSSION 
 
The  enzyme  ribonucleotide  reductase  is  essential  to 
maintain the levels of dNTPs necessary to support DNA 
replication  and  growth,  and  has  long  been  an  attractive 
target  for  anticancer  therapy.  Although  many  small 
molecule drugs have been shown to inhibit the activity of 
RR directly, only hydroxyurea has reached the clinic. The 
use of small-interfering RNA or antisense oligonucleotides 
to inhibit one or more subunits of this enzyme in a specific 
manner  represents  an  alternative  or  supplementary 
approach to small molecule drug treatment.  
 
As both RRM1 and RRM2 are needed to form the active 
ribonucleotide reductase enzyme, it is not surprising that 
the efficient knockdown of either subunit presented here 
led to extensive growth inhibition. In light of the essential 
role of RR in DNA replication and repair, it was somewhat 
surprising that early studies using antisense (Chen et al, 
2000;  Lee  et  al,  2006)  or  RNAi  (Oguri,  et  al,  2006; 
Nakahira et al, 2007) to silence the expression of either 
RR subunit did not report the level of inhibition of cell 
growth  that  we  observed.  Our  results,  and  those  from 
recent studies targeting RRM2 with siRNAs (Avolio et al, 
2007; Heidel et al, 2007), suggest that this is likely due to 
a combination of incomplete transfection and or inefficient 
silencing. To accurately assess the effects of knockdown 
when  the  target  gene  is  essential  for  cell  growth,  it  is 
important to deliver an effective siRNA to as many cells as 
possible.  With  our  optimized  transfection  protocol,  we 
were able to transfect >99% of cells as determined with a 
fluorescently-labeled  siRNA,  and  the  effects  on  cell 
growth  suggest  a  similar  transfection  rate in subsequent 
studies  with  RRM1-  or  RRM2-specific  siRNAs.  Our 
results  comparing  forward  and  reverse  transfection 
contrast somewhat with the pioneering study using FITC-
labelled  siRNAs  as  a  marker  of  transfection  in  which 
forward transfection was reported to deliver siRNAs to all 
cells  (Holen  et  al,  2002).  Nevertheless,  we  have  seen 
potent and enduring growth inhibition only with reverse 
transfection  at  low  cell  density.  With  either  forward 
transfection or higher cell densities, growth inhibition was 
observed for at most 96 hr (data not shown), suggesting 
that  under  these  conditions  an  untransfected  (or  poorly 
transfected)  population  of  cells  received  insufficient 
siRNA to cause a growth inhibitory reduction of RRM1 or 
RRM2.  Parallels  can  be  seen  in  the  study  by  Lin  and 
colleagues (Lin et al, 2007) that aimed to generate cells 
stably  transduced  with  a  construct  expressing  RRM1-
specific  shRNA;  none  of  the  stable  transfectants  were 
found  to  have  decreased  RRM1  expression,  suggesting 
that  reducing  RRM1  below  a  certain  threshold  is 
incompatible  with  cell  growth  and  thus  also  with  the 
expansion of clones with substantial knockdown.  
 
A number of previous studies have investigated the effects 
of  silencing  the  genes  for  one  or  other  RR  subunit  but 
none  has  compared  knockdown  of  each  subunit  in  the 
same cells. Our results show that  following  transfection 
with  equimolar  concentrations  of  RRM1-  and  RRM2-
specific  siRNAs,  RRM1  knockdown  in  vitro  results  in 
more effective and longer-lasting  growth inhibition than 
that achieved following the knockdown of RRM2. Not all 
siRNAs inhibited growth equally, however, with RRM1-1 
and RRM2-2 markedly less active than the others. This is 
consistent with the positional effects of siRNA target site 
on the extent of knockdown first reported in the case of 
human tissue factor (Holen et al, 2002). Also, cells recover 
from  RRM2  knockdown  faster  and  xenografts  derived 
from  cells  transfected  with  RRM2  siRNA  form  more 
readily  and  grow  faster  than  those  resulting  from 
implantation of RRM1-transfected cells. Although we saw  
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similar levels of knockdown of RRM1 and RRM2 mRNA 
and protein following transfection of either A549 or HCT-
116 cells with subunit specific siRNAs, several possible 
explanations  could  account  for  the  increased  cytotoxic 
effects of RRM1 siRNA. First, RRM2 mRNA amplifies 
more readily in our real-time PCR experiments suggesting 
that the basal levels of RRM2 mRNA are approximately 4-
fold  greater  than  those  of  RRM1,  similar  to  the  results 
found  in  patients  following  treatment  with  RRM2 
targeting  AS-ODN  (Juhasz  et  al,  2006).  Alternatively, 
there may be some subtle differences in the knockdown 
achieved by the siRNAs used in our assays that we have 
not been able to accurately determine. Regardless of the 
underlying  explanation,  it  is  clear  that,  at  equimolar 
concentrations,  RRM1-targeting  siRNA  is  more  growth 
inhibitory than siRNA targeting RRM2. 
 
In  cell  lines  resistant  to  gemcitabine  or  hydroxyurea, 
upregulation  of  either  RRM1  (Davidson  et  al,  2004; 
Jordheim et al, 2005) or RRM2 (Zhou et al, 1995; Goan et 
al, 1999) has been demonstrated and RRM1 was found 
upregulated following selection with gemcitabine in vivo 
(Bergman  et  al,  2005).  Our  initial  attempts  to  assess 
whether knockdown of RRM1 or RRM2 sensitize cells to 
the effects of drugs known to target or interact with these 
polypeptides were hampered by the efficiency with which 
the siRNAs we used inhibited cell growth. Only when we 
reduced  the  siRNA  concentrations  to  picomolar  levels 
were we able to observe sensitization to gemcitabine and 
hydroxyurea,  drugs  known  to  interact  with  RRM1  and 
RRM2,  respectively.  The  2  to  5-fold  increase  in 
gemcitabine  sensitivity  following  sub-growth  inhibitory 
RRM1 knockdown correlates well with a previous study 
(Bepler  et  al,  2006),  as  do  the  similar  increases  in 
hydroxyurea  sensitization  seen  after  low-level  RRM2 
knockdown (Lin et al, 2004). Both of these  studies are 
interesting in that they used stably expressed shRNAs to 
knockdown RRM1 or RRM2 but did not report (Bepler et 
al, 2006) or observe (Lin et al, 2004) changes in growth 
of their stable transfectants despite knockdown of greater 
than  80%.  In  contrast,  Lin  and  colleagues  failed  to 
generate  transfectants  stably  expressing  RRM1  shRNA 
(Lin  et  al,  2007).  This  suggests  that  there  exists  a 
threshold for RRM1 or RRM2 expression, below which 
cells are unable to survive, and further suggests that the 
knockdown  we  observe  for  RRM1  and  RRM2  exceeds 
this limit.  
 
The inability of small molecules to effectively inhibit RR 
function has led to silencing of RRM2 being proposed as 
a  possible  anticancer  treatment,  either  alone  or  in 
combination  with  gemcitabine  (Duxbury  et  al,  2004; 
Bepler et al, 2006). More recently siRNAs have been used 
to silence RRM2 and this has been shown to inhibit tumor 
cell growth both in vitro and in vivo (Avolio et al, 2007; 
Heidel  et  al,  2007).  Our  results  directly  comparing  the 
effects of RRM1 and RRM2 siRNAs suggest that RRM1 
silencing  is  a  more  effective  means  of  inhibiting  cell 
growth than RRM2 knockdown. It is also apparent from 
our  results  that  in  vitro  studies  of  the  effects  of  gene 
silencing  should  be  carried  out  with  optimized 
transfection protocols to ensure that the gene in question 
has  been  effectively  knocked  down  in  the  entire 
population of cells studied. As the majority of cells must 
be transfected for knockdown of either RRM1 or RRM2 
to be most effective in vitro, this will likely impact their 
success in inhibiting tumor growth in vivo. In the case of 
targeting  RRM2, even  transfecting  greater  than 99% of 
cells  prior  to  xenograft  formation,  only  partial  tumor 
growth  inhibition  was  observed.  Interestingly,  from  the 
view  of  a  therapeutic  application,  transfection  with  as 
little as 1 nM siRNA against either subunit led to growth 
arrest and apoptosis in vitro, whilst concentrations in the 
picomolar  range  resulted  in  a  marked  sensitization  to 
chemotherapeutic  drugs.  Taken  together  our  results 
suggest  that,  with  the  appropriate  tumor-selective 
delivery, siRNA targeting RRM1 could form the basis of 
a  therapeutic  strategy  for  cancer,  either  alone  or  in 
combination with gemcitabine. 
 
CONCLUSIONS 
 
• Stealth  siRNA-mediated  silencing  of  either  RRM1  or 
RRM2 in cancer cells was growth inhibitory at picomolar 
concentrations  when  an  optimized  transfection  method 
was  used,  and  RRM1  knockdown  was  more  growth 
inhibitory  when  cells  were  treated  with  equimolar 
concentrations of siRNA. 
 
• Knockdown  of  RRM1  or  RRM2  using  siRNA 
concentrations lower than those required to inhibit growth 
sensitized  cells  to  gemcitabine  and  hydroxyurea, 
respectively. 
 
• Pre-implantation silencing of RRM1 was more effective 
than RRM2 knockdown at inhibiting xenograft formation 
and growth in CD-1 nude mice. 
 
• RNAi-mediated silencing of RRM1 represents a potential 
strategy for cancer therapy that is both growth inhibitory 
and drug-sensitizing. 
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